Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06736574 · ClinicalTrials.gov registry record · Phase 3
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
A Phase 3 study of Heart Failure and Heart Failure With Reduced Ejection Fraction, sponsored by Cytokinetics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,800
- Enrollment target
- 20
- Study locations
NCT06736574: Recruiting Phase 3 study of Heart Failure and Heart Failure With Reduced Ejection Fraction, sponsored by Cytokinetics.
NCT06736574 is a Phase 3 study of Heart Failure and Heart Failure With Reduced Ejection Fraction that is actively recruiting participants, run by Cytokinetics. The registered enrollment target is 1,800 participants, below the 2,045-participant average among 397 other Heart Failure trials with a reported enrollment target (12% lower). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06736574, a Phase 3 study of Heart Failure and Heart Failure With Reduced Ejection Fraction, is actively recruiting participants, sponsored by Cytokinetics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,800 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.
Primary Outcome
Efficacy of omecamtiv mecarbil compared with placebo on the risk of HF outcomes in patients with symptomatic HFrEF and severely reduced ejection fraction in the setting of guideline-directed medical therapy per local standard of care.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Omecamtiv Mecarbil (OM)
Study Locations (20)
California
- National Heart Institute - Beverly Hills
- UC San Diego Health - Sulpizio Cardiovascular Center - La Jolla
- Nutrition Research Center (SPH) - Loma Linda
- Keck Medical Center of USC (outpatient clinic) - Los Angeles
- UCLA Medical Center Cardiovascular Clinic - Los Angeles
- University of California, Irvine Medical Center - Orange
- Sutter Institute for Medical Research (SIMR) - Sacramento
- UC Davis Health - Sacramento
- San Diego Cardiac Center - San Diego
- California Pacific Medical Center Van Ness Campus - San Francisco
- Kaiser Permanente Santa Clara - Santa Clara
- Stanford University Hospital / Stanford Health Care - Stanford
- Lundquist Institute for Biomedical Innovation at Harbor - UCLA Medical Center - Torrance
Connecticut
- Cardiology Associates of Fairfield County, P.C - Bridgeport
- Hartford Hospital - Hartford
- Yale New Haven Health Heart & Vascular Center Outpatient Services - New Haven
Alabama
- Advanced Cardiovascular, LLC - Alexander City
- University of Alabama at Birmingham - Birmingham
Arizona
- Pima Heart and Vascular Clinical Research - Tucson
Colorado
- Rocky Mountain Regional VA Medical Center - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,800 participants |
| Start Date | 2024-12-19 |
| Est. Completion | 2027-12 |
| Phase | Phase 3 |
What NCT06736574 shows while recruiting
NCT06736574 is an interventional study that assigns participants to a tested intervention. Its 1,800 participants enrollment target places it among the larger protocols in the corpus, below the 2,045-participant average among 397 other Heart Failure trials with a reported enrollment target (12% lower).
The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06736574 names 20 study sites across 5 states, led by California, Connecticut, Alabama.
Frequently Asked Questions
What is clinical trial NCT06736574 about?
NCT06736574 is a clinical study titled "Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction". The purpose of this study is to find out if the investigational drug called omecamtiv mecarbil can reduce the risk of the effects of heart failure, like hospitalization, transplantation, or death in patients with heart failure and severely reduced ejection fraction.
What is the current status of trial NCT06736574?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,800 participants. The study started on 2024-12-19. Estimated completion is 2027-12.
What conditions does trial NCT06736574 study?
This clinical trial studies the following conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction.
What interventions are being tested in trial NCT06736574?
The interventions under investigation include: Placebo (DRUG), Omecamtiv Mecarbil (OM) (DRUG).
Who is sponsoring clinical trial NCT06736574?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06736574 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06736574's enrollment target sits among peer trials
1,800 47th of 397 higher than 351 of 397 other Heart Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
- NCT04980794 · 1,800 participants · NA
The Happy Families Project: Testing the Effectiveness of a Conflict Resolution Program for Families
- NCT05258656 · 1,800 participants · NA
Childhood Activities Nutrition and Development Oversight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI